Optimization of Inflammatory Bowel Disease Cohort Studies in Asia

Wai K. Leung

doi:10.5217/ir.2015.13.3.208

Articles

Page Path: HOME > Intest Res > Volume 13(3); 2015 > Article

Special Review IBD and Epidemiology in Asia Optimization of Inflammatory Bowel Disease Cohort Studies in Asia: Wai K. Leung; Intestinal Research 2015;13(3):208-212.
DOI: https://doi.org/10.5217/ir.2015.13.3.208
Published online: June 9, 2015

Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong.

Correspondence to Wai K. Leung, Department of Medicine, Queen Mary Hospital, University of Hong Kong, 4/F, Professorial Block, 102 Pokfulam Road, Hong Kong. Tel: +852-2255-3750, Fax: +852-2816-2863, waikleung@hku.hk

• Received: April 28, 2015 • Revised: April 28, 2015 • Accepted: April 29, 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next

6,224 Views
36 Download
10 Web of Science
10 Crossref

Full Article

Download PDF

Abstract
INTRODUCTION
AIMS OF COHORT STUDIES
COHORT STUDY DESIGN
IMPLEMENTATION OF PROSPECTIVE COHORT STUDIES
THE HONGKONG IBD REGISTRY
CONCLUSIONS
Acknowledgments
ACKNOWLEDGEMENT
NOTES
REFERENCES

Abstract

With the incidence of inflammatory bowel disease (IBD) increasing rapidly in many Asian countries, including Hong Kong, it is important that patient characteristics are better understood. For example, are the phenotypes, behaviors, complications, and even treatment responses found in Asian patients similar to those of their Western counterparts? To formally address these questions, a properly designed local cohort study is needed. Whilst IBD is still relatively uncommon in Asia, the establishment of a local IBD registry will significantly contribute to the answering of these questions. The Hong Kong IBD registry was established to fill the gap in the understanding of IBD patients, and to foster research into IBD in Hong Kong. The Hong Kong IBD registry is a territory-wide registry that includes all public hospitals in Hong Kong. We included all IBD patients who were currently receiving medical care at these hospitals. With the help of the central computer medical record system of the Hospital Authority of Hong Kong, all clinical events, medications usage, endoscopy records, and laboratory results of patients in the registry were captured. Apart from data collection, the registry is also establishing a bio-specimen bank of blood and stool samples of IBD patients for future research. The IBD registry is a very useful platform for population-based studies on IBD in Asia.
Keywords: Crohn disease; Inflammatory bowel diseases; Registries; Colitis, Ulcerative

INTRODUCTION

The incidence of IBD has been rising rapidly globally over the past few decades.1 There are wide geographic variations in the incidence and prevalence of IBD, and the disease is still more prevalent in Western countries than in Asia. In Asia, IBD is a rapidly emerging disease, particularly in the more developed countries of the region.2 3 A recent multi-country epidemiological study showed that the incidences of both CD and UC are still significantly lower in most Asian countries than in Australia.4 However, there are wide variations in the incidence of IBD across different Asian countries.

Since most published epidemiological data on IBD originates from Western countries, it remains to be determined whether data published in the West can be directly translated to the Asian setting. In particular, there is a pressing need to validate whether the disease phenotypes, responses to various treatments, and complications are comparable between Asian patients and their Western counterparts.

To this end, our Asian colleagues have produced many high-quality publications on the epidemiology of IBD in Asia. A simple search of the PubMed (as in April 2015) database with the keyword "IBD epidemiology in Asia" yields an increasing number of publications over the past few decades (Fig. 1). There were virtually no publications on this topic before the 70's, followed by a surge in the late 90's. However, many of these studies, particularly the early ones, involved small numbers of patients and were based on a few highly selected tertiary referral centers in Asia, which may limit the validity of the results when generalized to the broader region.

With the increasing number of IBD patients in Asia, better design and organization of epidemiological cohort studies are needed. This article attempts to discuss ways of optimizing IBD cohort studies, and to share our early experiences of the recently established Hong Kong IBD registry.

AIMS OF COHORT STUDIES

Similar to randomized controlled studies, cohort studies are designed to address clinical questions relevant to disease pathogenesis, characteristics, or management. For IBD, common goals of cohort studies are to characterize epidemiological data on IBD patients, and to collect information on treatment responses and disease related complications and health care utilization. They are also useful in determining other aspects of disease, including various social and psychological parameters.

Prospective cohort studies are capable of obtaining bio-specimens such as colonic biopsy and fecal or blood samples for use in biobanks, which are very useful in subsequent genome-wide association studies as well as microbiota analyses.

COHORT STUDY DESIGN

Cohort studies are a form of longitudinal study that attempts to analyze target outcomes in a group of individuals. The outcomes can be the occurrence of a target disease among those with exposure to certain risk factors, or the development of a complication among those with a certain disease. In either case, the incidence of disease or the relative risk of exposure can be precisely estimated. In contrast to prospective randomized clinical trials that usually involve intervention, cohort studies are usually observational in nature and patients are not randomly assigned to a specific treatment. This aspect is inferior to randomized controlled trials, as this approach may introduce bias.

The design of these observational studies could be further classified into "prospective" and "retrospective". For instance, a prospective IBD cohort enrolls all eligible IBD patients and follows them longitudinally. All relevant clinical and epidemiological information is recorded at baseline, and updated at intervals during the follow-up period. This may limit recall bias when compared to retrospective cohort studies when the target outcome has already developed. However, some information collected is still retrospectively recalled, particularly in patients with longstanding disease. An inception cohort captures all patients newly diagnosed with IBD only, which minimizes these potential recall biases due to long lag times. This is extremely useful for epidemiological studies designed to determine incidence and exposure. Due to the prospective nature of these studies, they can provide accurate relative risk or risk ratio estimation of target outcomes. Unlike randomized trials that typically assess a single primary outcome, multiple outcomes can be measured. However, inception cohort studies usually require long follow-up periods, and are generally expensive. Problems with patients being lost to follow-up can create uncertainties in data analysis and potential bias.

A retrospective cohort study is conceived after some individuals have already developed the outcomes, e.g., the occurrence of IBD or its related complications. This type of study does not require long follow-up duration and is particularly useful for rare diseases, such as IBD in Asia. These studies are also less costly than prospective cohort studies. Unlike in prospective studies, temporal relationships usually cannot be determined. It is also important to adjust for potential confounding factors in retrospective cohort studies, particularly in selecting cases and determining exposures.

IMPLEMENTATION OF PROSPECTIVE COHORT STUDIES

Although intervention is usually lacking for cohort studies, the design and execution, particularly for a prospective cohort study, is very similar to a randomized controlled trial. The effort and resources needed for this kind of study would be comparable to a prospective interventional study. A good example of a long-term cohort study is the Framingham Heart Study, which was started in 1948.5 There are also many examples of long-term IBD cohort studies present in the literature (Table 1).6 7 8 9 10 11 12 13 14 15 Although most of these data are from Western countries, there are a few ongoing Asian cohort studies.4 16

1. Data Collection

In prospective IBD cohort studies, like inception cohort studies, all patients are identified at baseline and are followed-up longitudinally for target outcomes like the development of complications, mortality, surgical resection etc. Unfortunately, some of these target outcomes may not be identified at the beginning of the study, and are sometimes only considered many years after the study has started. Hence, it is vital to carry out comprehensive and detailed planning for baseline data collection. How often this information needs to be updated is equally important. Since the frequency and extent of follow-up data collection can have major implications on resources and patient compliance, it is prudent to be realistic and practical. Due to the differences in health care systems in different countries, the availability of centralized electronic medical record systems or other similar administrative databases helps to reduce the workload of database maintenance. With long anticipated follow-up durations, mechanisms should be in place to identify patients who have been lost to follow-up due to various reasons.

2. Resources

A team of dedicated IBD researchers is the most important asset of any IBD cohort study. This team should comprise gastroenterologists with a special interest in IBD, research assistants, biostatisticians, technicians, and other related health care personnel. With the many parties involved, regular meetings and progress reports are needed to update all members. A transparent and pre-defined mechanism of sharing the intellectual property obtained from this kind of cohort study, like authorships in publications and the share of patents, is also crucial to maintaining team spirit and avoiding future conflicts. It may also be necessary to establish a publication subcommittee to oversight all research-related publications. The long-term storage of bio-specimens requires proper designated storage space (or freezers) and staff, which can have long-term implications on resource utilization. It is also important to clearly define the rules and regulations governing the future usage of these bio-specimens at the beginning of the study.

As mentioned previously, obtaining adequate funding is another important task for investigators. With the long follow-up duration (sometimes up to a few decades) of cohort studies, the provision of continuous funding support can be a problem for many non-governmental sponsored registries. Hence, a realistic estimate of the sustainability of this cohort study and a frequent revision of the budget may be necessary, particularly for prospective cohort studies.

3. Regulatory Issues

To ensure compliance with various regulatory authorities, approval from all local institutional review boards concerned should be obtained prior to the implementation of the study. This process can be very time consuming when multiple institutions are involved. Proper informed consent should also be obtained for patients enrolling in prospective studies, and particularly for studies involving the storage of patients' clinical specimens. Special attention should also be directed to maintaining patients' confidentially in the database. Internet security is another important issue that should not be overlooked, particularly with the use of open web-based databases. However, the use of anonymous data may pose problems in subsequent follow-up and data validation.

THE HONGKONG IBD REGISTRY

The Hong Kong IBD Registry was established in 2011 to systematically collect clinical and epidemiological data from IBD patients attending public hospitals in Hong Kong. The registry aims to fill the knowledge gap in the understanding of IBD patients and foster IBD research in Hong Kong. It is a territory-wide registry that includes all public hospitals in Hong Kong. The public hospital system is directly funded by the Hong Kong Government, and is available to all local residents at a minimal cost. It currently provides more than 90% of in-patient services in Hong Kong. The current registry covers 13 public hospitals with a catchment area of more than 7.3 million people. The registry was approved by the local Institutional Review Boards (IRBs) of each individual hospital. Funding was provided by local philanthropists and the pharmaceutical industry, both of which have no role in the daily operations of the registry. A central web-based database was used for data entry from individual participating hospitals. All patients were provided with a unique patient number such that no confidential patient information was stored in the central database.

We prospectively enrolled all patients with a confirmed diagnosis of IBD including CD, UC, and indeterminate colitis. With the help of the central computer medical record system of the Hospital Authority of Hong Kong, which essentially captured all clinical events, prescription histories, endoscopy records, and laboratory results of these patients, important clinical information could be updated periodically. As of April 2014, we collected information from more than 2,200 IBD patients. Results of some of the baseline analyses of these patients were presented in Digestive Disease Week 2015. Apart from data collection, the registry is also setting up a bio-specimen bank of blood and stool samples of IBD patients for future genomic and microbiota studies.

CONCLUSIONS

It is an exciting moment for IBD research in the Asia Pacific region, where the disease is emerging rapidly. The formation of IBD study groups and local IBD registries would help to produce valuable epidemiological data on patients, and will ultimately help to transform the care of IBD patients in this region.

Acknowledgments

ACKNOWLEDGEMENT

I would like to express my gratitude to all investigators who participated in the Hong Kong IBD Registry.

NOTES

Financial support: None.

Conflict of interest: None.

REFERENCES

1. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142:46–54.PMID: 22001864.Article PubMed
2. Thia KT, Loftus EV Jr, Sandborn WJ, Yang SK. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol 2008;103:3167–3182.PMID: 19086963.Article PubMed
3. Prideaux L, Kamm MA, De Cruz PP, Chan FK, Ng SC. Inflammatory bowel disease in Asia: a systematic review. J Gastroenterol Hepatol 2012;27:1266–1280.PMID: 22497584.Article PubMed
4. Ng SC, Tang W, Ching JY, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study. Gastroenterology 2013;145:158–165.PMID: 23583432.Article PubMed
5. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J 3rd. Factors of risk in the development of coronary heart disease-six year follow-up experience. The Framingham Study. Ann Intern Med 1961;55:33–50.PMID: 13751193.Article PubMed
6. Gower-Rousseau C, Vasseur F, Fumery M, et al. Epidemiology of inflammatory bowel diseases: new insights from a French population-based registry (EPIMAD). Dig Liver Dis 2013;45:89–94.PMID: 23107487.Article PubMed
7. Lennard-Jones JE, Shivananda S. EC-IBD Study Group. Clinical uniformity of inflammatory bowel disease a presentation and during the first year of disease in the north and south of Europe. Eur J Gastroenterol Hepatol 1997;9:353–359.PMID: 9160197.Article PubMed
8. Vind I, Riis L, Jess T, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol 2006;101:1274–1282.PMID: 16771949.Article PubMed
9. Pittet V, Juillerat P, Mottet C, et al. Cohort profile: the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). Int J Epidemiol 2009;38:922–931.PMID: 18782896.Article PubMed PDF
10. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374:1617–1625.PMID: 19837455.Article PubMed
11. Ramadas AV, Gunesh S, Thomas GA, Williams GT, Hawthorne AB. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut 2010;59:1200–1206.PMID: 20650924.Article PubMed
12. Martín-de-Carpi J, Rodríguez A, Ramos E, et al. Increasing incidence of pediatric inflammatory bowel disease in Spain (1996-2009): the SPIRIT Registry. Inflamm Bowel Dis 2013;19:73–80.PMID: 22535573.Article PubMed
13. Bernstein CN, Blanchard JF, Rawsthorne P, Wajda A. Epidemiology of Crohn's disease and ulcerative colitis in a central Canadian province: a population-based study. Am J Epidemiol 1999;149:916–924.PMID: 10342800.Article PubMed PDF
14. Hou JK, Kramer JR, Richardson P, Mei M, El-Serag HB. The incidence and prevalence of inflammatory bowel disease among U.S. veterans: a national cohort study. Inflamm Bowel Dis 2013;19:1059–1064.PMID: 23448789.Article PubMed PMC
15. Long MD, Crandall WV, Leibowitz IH, et al. Prevalence and epidemiology of overweight and obesity in children with inflammatory bowel disease. Inflamm Bowel Dis 2011;17:2162–2168.PMID: 21910178.Article PubMed
16. Ishige T, Tomomasa T, Takebayashi T, et al. Inflammatory bowel disease in children: epidemiological analysis of the nationwide IBD registry in Japan. J Gastroenterol 2010;45:911–917.PMID: 20232217.Article PubMed

Fig. 1

Number of publications in PubMed on the epidemiology of IBD in Asia.

Table 1

Examples of Population-Based IBD Registries

Continent	Reference	Name of registry	Countries	Design	Year	No. of patients
Europe
	6	Epimad registry	Northern France	Inception cohort	1988	18,170
	7	EC-IBD study group	Europe and Israel	Inception cohort	1991	1,145
	8	Danish CD database	Denmark	Prospective	2003	562
	9	Swiss IBD cohort study group	Switzerland	Prospective	2003	1,020
	10	CESAME study group	France	Prospective	2004	19,486
	11	Cardiff	UK	Retrospective	1986-2003	341
	12	SPIRIT registry	Spain	Retrospective	1996-2009	2,107 children
North America
	13	University of Manitoba IBD research registry	Canada	Retrospective	1985	NA
	14	Veterans Affairs	USA	Retrospective	1998-2009	43,114
	15	ImproveCareNow Collaborative for pediatric IBD	USA	Multi-center registry	2007-2008	1,598 children
Asia-Pacific
	16	Japanese nationwide IBD registry	Japan	Prospective	1975	NA
	4	ACCESS study group	Asia-Pacific	Inception cohort	2011	419
		Hong Kong IBD registry	Hong Kong	Prospective	2013	2,220

EPIMAD, registre des maladies inflammatoires du tube digestif du nord-ouest de la France; EC-IBD, European collaborative study group of inflammatory bowel disease; CESAME, cancers et surrisque associé aux maladies inflammatoires intestinales en France; SPIRIT, sociedad española de gastroenterología hepatología nutrición pediátrica; ACCESS, Asia-pacific crohn's and colitis epidemiology study; NA, not available.

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

The effectiveness and safety of vedolizumab induction for moderate to severe ulcerative colitis for Asia patient: A real practice observational study
Chia-Jung Kuo, Puo-Hsien Le, Wei-Chen Tai, Keng-Liang Wu, Hsu-Heng Yen, Chih-Wei Yen, Shui-Yi Tung, Chen-Shuan Chung, Ming-Yao Su, Cheng-Tang Chiu
Journal of the Formosan Medical Association.2022; 121(9): 1689. CrossRef
Indications, Postoperative Management, and Long-term Prognosis of Crohn’s Disease After Ileocecal Resection: A Multicenter Study Comparing the East and West
Jeanine H C Arkenbosch, Joyce W Y Mak, Jacky C L Ho, Evelien M J Beelen, Nicole S Erler, Frank Hoentjen, Alexander G L Bodelier, Gerard Dijkstra, Mariëlle Romberg-Camps, Nanne K H de Boer, Laurents P S Stassen, Andrea E van der Meulen, Rachel West, Oddeke
Inflammatory Bowel Diseases.2022; 28(Supplement): S16. CrossRef
Epidemiology and Natural History of Elderly-onset Inflammatory Bowel Disease: Results From a Territory-wide Hong Kong IBD Registry
Joyce Wing Yan Mak, Carmen Lok Tung Ho, Kylie Wong, Tsz Yan Cheng, Terry Cheuk Fung Yip, Wai Keung Leung, Michael Li, Fu Hang Lo, Ka Man Ng, Shun Fung Sze, Chi Man Leung, Steven Woon Choy Tsang, Edwin Hok Shing Shan, Kam Hon Chan, Belsy C Y Lam, Aric Josu
Journal of Crohn's and Colitis.2021; 15(3): 401. CrossRef
Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study
Choon Jin Ooi, Ida Normiha Hilmi, Hyo-Jong Kim, Umesh Jalihal, Deng-Chyang Wu, Dirk Demuth, Dirk Lindner, Shashi Adsul
Intestinal Research.2021; 19(1): 71. CrossRef
Efficacy and safety of vedolizumab in Crohn’s disease in patients from Asian countries in the GEMINI 2 study
Rupa Banerjee, Sai Wei Chuah, Ida Normiha Hilmi, Deng-Chyang Wu, Suk-Kyun Yang, Dirk Demuth, Dirk Lindner, Shashi Adsul
Intestinal Research.2021; 19(1): 83. CrossRef
Cancer risk and chemoprevention in Chinese inflammatory bowel disease patients: a population-based cohort study
Joyce Wing Yan Mak, Jacqueline So, Whitney Tang, Terry Cheuk Fung Yip, Wai Keung Leung, Michael Li, Fu Hang Lo, Ka Man Ng, Shun Fung Sze, Chi Man Leung, Steven Woon Choy Tsang, Edwin Hok Shing Shan, Kam Hon Chan, Belsy C.Y. Lam, Aric J. Hui, Wai Hung Chow
Scandinavian Journal of Gastroenterology.2020; 55(3): 279. CrossRef
Iranian Registry of Crohn’s and Colitis: study profile of first nation-wide inflammatory bowel disease registry in Middle East
Masoud M Malekzadeh, Alireza Sima, Sudabeh Alatab, Anahita Sadeghi, Nasser Ebrahimi Daryani, Payman Adibi, Iradj Maleki, Hassan Vossoughinia, Hafez Fakheri, Abbas Yazdanbod, Seyed Alireza Taghavi, Rahim Aghazadeh, Mohammad Hassan Somi, Kazem Zendedel, Hom
Intestinal Research.2019; 17(3): 330. CrossRef
Stopping anti‐tumour necrosis factor therapy in patients with perianal Crohn’s disease
Joyce Wing Yan Mak, Whitney Tang, Terry Cheuk Fung Yip, Zhi Hua Ran, Shu Chen Wei, Vineet Ahuja, Sudheer Kumar, Wai Keung Leung, Ida Hilmi, Julajak Limsrivilai, Satimai Aniwan, Belsy C. Y. Lam, Kam Hon Chan, Ka Man Ng, Chi Man Leung, Michael K. K. Li, Fu
Alimentary Pharmacology & Therapeutics.2019; 50(11-12): 1195. CrossRef
Direct health‐care cost utilization in Hong Kong inflammatory bowel disease patients in the initial 2 years following diagnosis
Lung‐Yi Mak, Siew C Ng, Irene O L Wong, Michael K K Li, F H Lo, Marc T L Wong, C M Leung, Steven W C Tsang, K H Chan, S F Sze, Edwin H S Shan, Belsy C Y Lam, Aric J Hui, Ivan F N Hung, Wai K Leung
Journal of Gastroenterology and Hepatology.2018; 33(1): 141. CrossRef
Significant Medical and Surgical Morbidity in Perianal Crohn’s Disease: Results from a Territory-Wide Study
Wing Yan Mak, Oi Sze Mak, Choon Kin Lee, Whitney Tang, Wai Keung Leung, Marc T L Wong, Alex Shun Fung Sze, Michael Li, Chi Man Leung, Fu Hang Lo, Belsy C Y Lam, Kam Hon Chan, Edwin Hok Shing Shan, Steven Woon Choy Tsang, Aric J Hui, Wai Hung Chow, Francis
Journal of Crohn's and Colitis.2018;[Epub] CrossRef

PubReader

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Optimization of Inflammatory Bowel Disease Cohort Studies in Asia

Intest Res. 2015;13(3):208-212. Published online June 9, 2015

DOI: https://doi.org/10.5217/ir.2015.13.3.208

XML Download

Figure

Related articles

Optimization of Inflammatory Bowel Disease Cohort Studies in Asia

Fig. 1 Number of publications in PubMed on the epidemiology of IBD in Asia.

Fig. 1

Optimization of Inflammatory Bowel Disease Cohort Studies in Asia

Table 1

Examples of Population-Based IBD Registries

Continent	Reference	Name of registry	Countries	Design	Year	No. of patients
Europe
	6	Epimad registry	Northern France	Inception cohort	1988	18,170
	7	EC-IBD study group	Europe and Israel	Inception cohort	1991	1,145
	8	Danish CD database	Denmark	Prospective	2003	562
	9	Swiss IBD cohort study group	Switzerland	Prospective	2003	1,020
	10	CESAME study group	France	Prospective	2004	19,486
	11	Cardiff	UK	Retrospective	1986-2003	341
	12	SPIRIT registry	Spain	Retrospective	1996-2009	2,107 children
North America
	13	University of Manitoba IBD research registry	Canada	Retrospective	1985	NA
	14	Veterans Affairs	USA	Retrospective	1998-2009	43,114
	15	ImproveCareNow Collaborative for pediatric IBD	USA	Multi-center registry	2007-2008	1,598 children
Asia-Pacific
	16	Japanese nationwide IBD registry	Japan	Prospective	1975	NA
	4	ACCESS study group	Asia-Pacific	Inception cohort	2011	419
		Hong Kong IBD registry	Hong Kong	Prospective	2013	2,220

Table 1 Examples of Population-Based IBD Registries